There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Castle Biosciences (CSTL – Research Report), Lonza Group Ltd (CH:LONN – Research Report) and GN Store Nord (GB:0K9P – Research Report) with bullish sentiments.
Castle Biosciences (CSTL)
In a report issued on August 3, Sung Ji Nam from Scotiabank maintained a Buy rating on Castle Biosciences, with a price target of $33.00. The company’s shares closed last Friday at $17.50.
According to TipRanks.com, Nam is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Castle Biosciences with a $34.86 average price target, representing a 100.3% upside. In a report issued on August 2, Robert W. Baird also maintained a Buy rating on the stock with a $30.00 price target.
See the top stocks recommended by analysts >>
GN Store Nord (GB:0K9P)
In a report issued on August 11, Maja Pataki from Kepler Capital maintained a Buy rating on GN Store Nord, with a price target of DKK213.00. The company’s shares closed last Friday at DKK171.63.
According to TipRanks.com, Pataki is ranked #8423 out of 8549 analysts.
Currently, the analyst consensus on GN Store Nord is a Moderate Buy with an average price target of DKK217.57.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CSTL:
- Castle Biosciences announces new TissueCypher study data published
- Castle Biosciences price target raised to $30 from $25 at Baird
- Castle Biosciences raises FY23 revenue view to $180M, consensus $174.47M
- Castle Biosciences reports Q2 EPS (70c), consensus (91c)
- Craig-Hallum says CareDx appears to look to Congress for help amid Castle reversal
